Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in...
Lanfu Information June 5, 2026
Tuoxin Pharmaceutical: Net profit loss of 11.8805 million yuan in the third quarter, a decrease of 1,258.62%
Tuoxin Pharmaceutical: Plans to establish a wholly-owned subsidiary with a registered capital of 50 million yuan
Tuoxin Pharmaceutical's subsidiary product Glyceryl Phosphoryl Choline has passed the US Self-GRAS certification
Tuoxin Pharmaceutical: Wholly-owned subsidiary obtains CNAS laboratory accreditation certificate
Tuoxin Pharmaceutical: Net loss of 18.2805 million yuan in the first half of 2025